Evidence map›Paper›PMID 34310827›Full record

ArticleJournal of applied clinical medical physics2021

Geometric and dosimetric accuracy of deformable image registration between average-intensity images for 4DCT-based adaptive radiotherapy for non-small cell lung cancer.

Yulun He, Guillaume Cazoulat, Carol Wu, Christine Peterson, Molly McCulloch, Brian Anderson, Julianne Pollard-Larkin, Peter Balter, Zhongxing Liao, Radhe Mohan and 1 more

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yulun HeDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-6258-4986
Guillaume CazoulatDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-2042-7602
Carol WuDepartment of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-1005-0995
Christine PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-3316-0468
Molly McCullochDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-7531-1263
Brian AndersonDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-2748-1444
Julianne Pollard-LarkinDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-1196-656X
Peter BalterDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhongxing LiaoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-2224-9478
Radhe MohanDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-3746-4557
Kristy BrockDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-9364-5040

Funding

Risk prediction and longitudinal assessment of cardiotoxicity and functional capacity trajectory in NSCLC patientsR01HL157273 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIAO, ZHONGXING · 2021 to 2025
$3.8M
Proton Therapy to Reduce Heart Damage for Lung Cancer PatientsR21CA222749 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIAO, ZHONGXING · 2019 to 2020
$388k
NCI NIH HHS R21 CA222749NHLBI NIH HHS R01 HL157273
6 · The paper itself

Abstract

purposeRe-planning for four-dimensional computed tomography (4DCT)-based lung adaptive radiotherapy commonly requires deformable dose mapping between the planning average-intensity image (AVG) and the newly acquired AVG. However, such AVG-AVG deformable image registration (DIR) lacks accuracy assessment. The current work quantified and compared geometric accuracies of AVG-AVG DIR and corresponding phase-phase DIRs, and subsequently investigated the clinical impact of such AVG-AVG DIR on deformable dose mapping. METHODS AND MATERIALS: Hybrid intensity-based AVG-AVG and phase-phase DIRs were performed between the planning and mid-treatment 4DCTs of 28 non-small cell lung cancer patients. An automated landmark identification algorithm detected vessel bifurcation pairs in both lungs. Target registration error (TRE) of these landmark pairs was calculated for both DIR types. The correlation between TRE and respiratory-induced landmark motion in the planning 4DCT was analyzed. Global and local dose metrics were used to assess the clinical implications of AVG-AVG deformable dose mapping with both DIR types.

resultsTRE of AVG-AVG and phase-phase DIRs averaged 3.2 ± 1.0 and 2.6 ± 0.8 mm respectively (p < 0.001). Using AVG-AVG DIR, TREs for landmarks with <10 mm motion averaged 2.9 ± 2.0 mm, compared to 3.1 ± 1.9 mm for the remaining landmarks (p < 0.01). Comparatively, no significant difference was demonstrated for phase-phase DIRs. Dosimetrically, no significant difference in global dose metrics was observed between doses mapped with AVG-AVG DIR and the phase-phase DIR, but a positive linear relationship existed (p = 0.04) between the TRE of AVG-AVG DIR and local dose difference.

conclusionsWhen the region of interest experiences <10 mm respiratory-induced motion, AVG-AVG DIR may provide sufficient geometric accuracy; conversely, extra attention is warranted, and phase-phase DIR is recommended. Dosimetrically, the differences in geometric accuracy between AVG-AVG and phase-phase DIRs did not impact global lung-based metrics. However, as more localized dose metrics are needed for toxicity assessment, phase-phase DIR may be required as its lower mean TRE improved voxel-based dosimetry.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAlgorithmsFour-Dimensional Computed TomographyHumansImage Processing, Computer-AssistedRadiotherapy Planning, Computer-Assisted4DCTadaptive radiotherapydeformable image registration accuracynon-small cell lung cancer

Identifiers

PMID34310827
PMCPMC8364273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.